Conference reports

Dolutegravir for younger children: results from the ODYSSEY trial

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

Featured 10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

WHO recommends dolutegravir-based ART regimens for all

High rates of viral suppression with low dose efavirenz in pregnant Zambian women

First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10

Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results

Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy

Fostemsavir: 96-week follow-up in people with multi-drug resistance

Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96

Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study

Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

Upcoming 10th IAS Conference on HIV Science (IAS 2019)

IAS 2019: late breaker highlights to look for

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs

Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine

Drug-drug interactions between efavirenz and levonorgestrel influenced by genetic variants 

Infant dolutegravir exposure through placental and breastmilk transfer  

Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s

13th INTEREST workshop 14–17 May 2019, Accra, Ghana

No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study

25th Annual BHIVA Conference (BHIVA 2019)

Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study

Management of testosterone deficiency in HIV positive people

Importance of including menopause and bone health in management of HIV positive women

Type 2 diabetes is often undermanaged in HIV positive people

Adopting new US blood pressure targets for HIV positive people could reduce cardiovascular-related deaths

Selected webcasts from BHIVA 2019

Conference on Retroviruses and Opportunistic Infections (CROI 2019) 4–7 March, 2019

INSTI and weight gain: reports from CROI 2019

B/F/TAF suitable for children from six years of age

25th Annual BHIVA Conference (BHIVA 2019)

BHIVA preconference: U=U and HIV and immigration detention

Conference on Retroviruses and Opportunistic Infections (CROI 2019): third reports

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

Paediatric dolutegravir update

Other cure related studies at CROI 2019

Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports

Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10

Capsid inhibitor GS-6297 shows potential for 3-monthly injections

First phase 1 results from bNAb PGT121 in HIV positive people

Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

Same-day ART is effective in San Francisco Rapid-ART clinic

Integrase inhibitors and neural tube defects: more data still needed

Double-dose levonorgestrel implant does not overcome interaction with efavirenz

Efavirenz and rifampicin together reduce levels of injectable contraception

Bedaquiline and delamanid safe when given together to treat drug resistant TB

Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes

Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports

UK patient likely to be the second person cured of HIV: two further cases at CROI 2019 of HIV remission after allogenic stem cell transplants

Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies

Viral reservoir can explain persistent low level viraemia with good adherence on ART

Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2

Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz

New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study

Dolutegravir can be given with 3HP to prevent TB without dose adjustment

Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

Shared housing compared to living alone: higher CD4, lower viral load and reduced inflammation in macaques

Selected webcasts at CROI 2019

i-Base Fit for Purpose report launched at CROI 2019

Pre-CROI Community HIV Cure Workshop 2019

27th International Workshop on HIV Drug Resistance and Treatment Strategies

Post navigation